Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.wexpharma.com
Number of Employees: 13
Year Founded: 1987
Total Amount Raised (CAD mm)†: 40.12
Total Rounds of Funding**:8
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
WEX Pharmaceuticals Inc., together with its subsidiaries, engages in the discovery, development, manufacture, and commercialization of various drug products for treating pain. Its drug products are derived from naturally occurring toxins. The company was incorporated in 1987 and is based in Vancouver, Canada. Wex Pharmaceuticals Inc. is a subsidiary of Pharmagesic (Holdings) Inc.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
57.6
EBITDA
(7.6)
EBIT
(7.7)
Cash & ST Invst.
17.1
P/Diluted EPS Before Extra
NM
Net Income
(7.7)
Total Debt
0.0
Price/Tang BV
1.9x
Capital Expenditure
(0.3)
Total Assets
33.4




U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
Currency in CAD in mm, LTM as of Dec-31-2010 TEV and Market Cap are calculated using a close price as of May-02-2011

Key Professionals
Name
Title
Evans, Don
Vice President of Corporate Communications
MacGregor, Robert R.
Head of Finance
Stafford, Peter Harry
Secretary
Sellers, Edward M.
Member of Scientific Advisory Board&Senior Medical Consultant-Phase Ia Phase Ib&c Phase IIa PhaseIIb

Key Board Members
Name
Title
Yu, Alan 
Chairman
Sellers, Edward M.
Member of Scientific Advisory Board&Senior Medical Consultant-Phase Ia Phase Ib&c Phase IIa PhaseIIb
Anderson, Simon J.
Independent Director
Berde, Charles 
Member of Scientific Advisory Board
Chu, Kee Hung
Director
du Souich, Patrick
Member of Scientific Advisory Board
Kim, Kyung Mann
Member of Scientific Advisory Board
Sibert, John Winton
Director
Strong, Kenneth 
Director
Toh, Kean Meng 
Director
Tong, Wai Tak 
Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
1090 West Pender Street Suite 420 | Vancouver, BC | V6E 2N7 | Canada
Phone: 604-683-8880   Fax: 604-683-8868

Parent Company
CK Life Sciences Int'l., (Holdings) Inc. (SEHK:775)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Iwt Bio Inc.

United States and Canada
-
-
-
-
Wex Medical Limited
Wex Medical Limited discovers, develops and manufactures drug products to treat pain. The company was formerly known as WEX Medical Instrumentation Co. Wex Medical Limited is based in North Point, Hong Kong. Wex Medical Limited operates as a subsidiary of WEX Pharmaceuticals Inc.

Asia / Pacific
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-12-2010
May-4-2011
Merger/Acquisition
Target
Wex Pharmaceuticals Inc.
CK Life Sciences Int'l., (Holdings) Inc. (SEHK:775)

7.10
Nov-27-2009
Dec-11-2009
Public Offering
Target
Wex Pharmaceuticals Inc.


32.57
Jul-16-2007
Oct-17-2007
Private Placement
Target
Wex Pharmaceuticals Inc.
CK Life Sciences Int'l., (Holdings) Inc. (SEHK:775)

20.61
Nov-25-2006
Jan-9-2007
Private Placement
Target
Wex Pharmaceuticals Inc.


1.34
Aug-21-2006
Cancelled
Private Placement
Target
Wex Pharmaceuticals Inc.


1.85
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jan-03-2023
Product-Related Announcements
Wex Pharmaceuticals Inc. Enrolls the First Patient in The Phase 2b Clinical Trial Evaluating the Efficacy and Safety of Halneuron(R) In the Treatment of Chemotherapy-Induced Neuropathic Pain
Jan-08-2019
Company Conference Presentations
Wex Pharmaceuticals Inc. Presents at Biotech Showcase 2019, Jan-07-2019 04:15 PM
Jun-04-2018
Company Conference Presentations
Wex Pharmaceuticals Inc. Presents at BIO International Convention, Jun-04-2018
Jan-08-2018
Company Conference Presentations
Wex Pharmaceuticals Inc. Presents at 10th Annual Biotech Showcase 2018, Jan-08-2018
Jan-07-2018
Company Conference Presentations
WEX Pharmaceuticals Inc. Presents at BIO One-on-One Partnering™, Jan-07-2018

M&A Advisors
Ernst & Young Orenda Corporate Finance Inc.


Advisors
Most Recent Auditor
Deloitte & Touche LLP
M&A Advisors
Ernst & Young Orenda Corporate Finance Inc.
Private Placement Advisors
Fasken Martineau DuMoulin LLP, Jennings Capital Inc., Union Securities Ltd.
Public Offering Advisors
Deloitte & Touche LLP (Canada), Fasken Martineau LLP


Most Recent Auditor
Deloitte & Touche LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 07, 2023 01:24 AM
Wex Pharmaceuticals Inc.
WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review
Reports
57
GlobalData

Jun 07, 2023 03:31 AM
Wex Pharmaceuticals Inc.
WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review
Reports
51
GlobalData

Mar 08, 2023 02:32 AM
Wex Pharmaceuticals Inc.
WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review
Reports
51
GlobalData

Dec 07, 2022 03:18 AM
Wex Pharmaceuticals Inc.
WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review
Reports
51
GlobalData

Sep 12, 2022 04:33 AM
Wex Pharmaceuticals Inc.
WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review
Reports
50
GlobalData

Jun 13, 2022 05:20 AM
Wex Pharmaceuticals Inc.
WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review
Reports
50
GlobalData

Mar 11, 2022 01:44 AM
Wex Pharmaceuticals Inc.
WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review
Reports
50
GlobalData

Dec 13, 2021 02:27 AM
Wex Pharmaceuticals Inc.
WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review
Reports
50
GlobalData

Sep 10, 2021 08:48 AM
Wex Pharmaceuticals Inc.
WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review
Reports
42
GlobalData

Dec 08, 2020 01:50 AM
Wex Pharmaceuticals Inc.
WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review
Reports
42



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
CK Life Sciences Int'l., (Holdings) Inc.
0
(399,010,876)
Huang MBA, Ph.D., Bin 
0
(5,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Drug Products, Halneuron (Future), Tetrodin (Future), Tocudin (Future)


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
May-06-2011
Wex Pharmaceuticals Inc.
SEDAR
Securities Acquisition Filings (Early Warning)
79 KB
May-06-2011
Wex Pharmaceuticals Inc.
SEDAR
Change in Corporate Structure
95 KB
May-05-2011
Wex Pharmaceuticals Inc.
SEDAR
Management Proxy Materials
97 KB
May-05-2011
Wex Pharmaceuticals Inc.
SEDAR
Documents Affecting the Rights of Security Holders
4 MB
May-05-2011
Wex Pharmaceuticals Inc.
SEDAR
News Releases
19 KB
May-03-2011
Wex Pharmaceuticals Inc.
SEDAR
News Releases
13 KB
Apr-28-2011
Wex Pharmaceuticals Inc.
SEDAR
Documents Affecting the Rights of Security Holders
99 KB
Apr-28-2011
Wex Pharmaceuticals Inc.
SEDAR
Documents Affecting the Rights of Security Holders
134 KB
Apr-12-2011
Wex Pharmaceuticals Inc.
SEDAR
Management Proxy Materials
50 KB
Apr-11-2011
Wex Pharmaceuticals Inc.
SEDAR
News Releases
16 KB

Key Board Members Details
Name
Title
Phone
Fax
Email
Yu, Alan 
Chairman
604-683-8880
604-683-8868
-
Sellers, Edward M.
Member of Scientific Advisory Board&Senior Medical Consultant-Phase Ia Phase Ib&c Phase IIa PhaseIIb
604-683-8880
604-683-8868

Anderson, Simon J.
Independent Director
604-683-8880
604-683-8868
simon@s2management.ca
Berde, Charles 
Member of Scientific Advisory Board
604-683-8880
604-683-8868

Chu, Kee Hung
Director
604-683-8880
604-683-8868
-
du Souich, Patrick
Member of Scientific Advisory Board
604-683-8880
604-683-8868
-
Kim, Kyung Mann
Member of Scientific Advisory Board
604-683-8880
604-683-8868
-
Sibert, John Winton
Director
604-683-8880
604-683-8868

Strong, Kenneth 
Director
604-683-8880
604-683-8868
-
Toh, Kean Meng 
Director
604-683-8880
604-683-8868

Tong, Wai Tak 
Director
604-683-8880
604-683-8868

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Evans, Don
Vice President of Corporate Communications
604-683-8880
604-683-8868
-
MacGregor, Robert R.
Head of Finance
604-683-8880
604-683-8868
-
Stafford, Peter Harry
Secretary
604-683-8880
604-683-8868

Sellers, Edward M.
Member of Scientific Advisory Board&Senior Medical Consultant-Phase Ia Phase Ib&c Phase IIa PhaseIIb
604-683-8880
604-683-8868

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
